Detalhe da pesquisa
1.
Sitravatinib combined with PD-1 blockade enhances cytotoxic T-cell infiltration by M2 to M1 tumor macrophage repolarization in esophageal adenocarcinoma.
Carcinogenesis
; 45(4): 210-219, 2024 Apr 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-38019590
2.
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer.
N Engl J Med
; 384(13): 1191-1203, 2021 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33789008
3.
Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal Adenocarcinoma.
Oncology (Williston Park)
; 37(4): 176-183, 2023 04 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-37104758
4.
CSF-1R inhibitor, pexidartinib, sensitizes esophageal adenocarcinoma to PD-1 immune checkpoint blockade in a rat model.
Carcinogenesis
; 43(9): 842-850, 2022 10 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-35552655
5.
A blood-based circulating microbial metagenomic panel for early diagnosis and prognosis of oesophageal adenocarcinoma.
Br J Cancer
; 127(11): 2016-2024, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36097175
6.
Targeting the Hedgehog Pathway Using Itraconazole to Prevent Progression of Barrett's Esophagus to Invasive Esophageal Adenocarcinoma.
Ann Surg
; 273(6): e206-e213, 2021 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31290765
7.
Healthcare utilization and total costs of care among patients with advanced metastatic gastric and esophageal cancer.
Future Oncol
; 17(3): 291-299, 2021 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-32996811
8.
Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial.
Lancet Oncol
; 21(8): 1066-1076, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32653053
9.
The emerging role of immunotherapy for esophageal cancer.
Curr Opin Gastroenterol
; 35(4): 337-343, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31045596
10.
Emerging Multimodality Approaches to Treat Localized Esophageal Cancer.
J Natl Compr Canc Netw
; 17(8): 1009-1014, 2019 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31390584
11.
The Dynamic and Transient Immune Microenvironment in Locally Advanced Esophageal Adenocarcinoma Post Chemoradiation.
Ann Surg
; 268(6): 992-999, 2018 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-28806299
12.
A Randomized Phase II Study of Metformin plus Paclitaxel/Carboplatin/Bevacizumab in Patients with Chemotherapy-Naïve Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer.
Oncologist
; 23(7): 859-865, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29487223
13.
Serial Endoscopic Evaluation of Esophageal Disease in a Cancer Model: A Paradigm Shift for Esophageal Adenocarcinoma (EAC) Drug Discovery and Development.
Cancer Invest
; 36(7): 363-370, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-30142016
14.
Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma.
Gut
; 66(5): 794-801, 2017 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-26801886
15.
PI3K/mTOR Dual Inhibitor, LY3023414, Demonstrates Potent Antitumor Efficacy Against Esophageal Adenocarcinoma in a Rat Model.
Ann Surg
; 266(1): 91-98, 2017 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-27471841
16.
Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial.
Lancet Oncol
; 17(5): 642-50, 2016 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-27080216
17.
Immunotherapy in upper GI malignancies.
Curr Treat Options Oncol
; 16(5): 20, 2015 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-25859830
18.
Delivering maximum clinical benefit at an affordable price: engaging stakeholders in cancer care.
Lancet Oncol
; 15(3): e112-8, 2014 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-24534294
19.
Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial.
Lancet Oncol
; 15(2): 191-200, 2014 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-24439931
20.
First-Line Nivolumab and Relatlimab Plus Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma: The Phase II RELATIVITY-060 Study.
J Clin Oncol
; : JCO2301636, 2024 May 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-38723227